CathWorks, a leader in digital health technology, has received significant recognition from the Society for Cardiovascular Angiography & Interventions (SCAI) regarding its FFRangio System. On February 4, 2026, SCAI published an expert opinion that highlights the evolving role of angiography-derived physiology (ADP) as a groundbreaking, wire-free technique for assessing coronary artery disease.
The expert opinion elaborates on the technological advancements of ADP, which utilizes artificial intelligence (AI) to extract physiologic insights from standard angiograms. This innovative approach marks a substantial shift in practices within catheterization labs, providing healthcare professionals with more accurate tools for diagnosing and treating cardiovascular conditions.
The CathWorks FFRangio System distinguishes itself within the ADP landscape. It integrates cutting-edge AI and computational science to derive physiologic data from three routine angiograms, employing a unique resistance-based computational model. As noted in the SCAI document, “FFRangio is the only technology that provides multivessel FFR values across the entire coronary tree, including side branches.” This capability enhances the assessment of functional disease and supports planning for percutaneous coronary interventions (PCI), areas where competing technologies may fall short.
Clinical performance data reinforce the advantages of the FFRangio System. In a pooled analysis of five prospective studies, including the pivotal FAST-FFR study, the system demonstrated a remarkable diagnostic accuracy of 93%. Furthermore, it exhibited comparable one-year rates of major adverse cardiac events (MACE) to traditional invasive FFR methods, as established in both real-world registries and the PROVISION randomized controlled trial, which involved 400 patients.
The SCAI expert opinion emphasizes the variability among ADP systems, particularly concerning imaging requirements, workflow integration, and computational methodologies. It asserts that the clinical data derived from these platforms should be interpreted based on specific validation studies. Notably, the report identifies the CathWorks FFRangio as the only FDA-approved ADP platform that provides comprehensive multi-vessel coronary physiology and a suite of PCI planning tools.
CathWorks’ President and CEO, Ramin Mousavi, expressed optimism about the growing body of clinical evidence supporting the FFRangio System. He stated, “With the rapidly expanding clinical evidence base for CathWorks FFRangio, we look forward to the U.S. and European guidelines incorporating peer-reviewed evidence-based technology specific recommendations that will broaden adoption of physiology overall, ultimately optimizing procedural decision-making and improving patient outcomes.”
As cardiovascular disease remains a leading cause of morbidity and mortality globally, innovations like the CathWorks FFRangio System are crucial for enhancing diagnostic accuracy and treatment efficacy. This recognition from SCAI may pave the way for broader acceptance and implementation of advanced physiological assessment technologies in the clinical setting, ultimately benefiting patients worldwide.
For further information, visit www.cath.works or follow CathWorks on LinkedIn.
